HealthyPhase 1NCT06797674
A Study of the Effect Efavirenz on the Plasma Levels of MK-7602 in Healthy Participants (MK-7602-005)
A Phase 1 study testing MK-7602 and Efavirenz in people with Healthy, run by Merck Sharp & Dohme LLC at 1 site in United States.
Trial summary
The goal of the study is to learn what happens to levels of MK-7602 in a healthy person's body over time. Researchers will compare what happens to MK-7602 in the body when it is given with or without another medicine called efavirenz, and when it is given with or without a meal. Read more about this study
- Who is it for?
- Ages 18 to 60 yearsHealthy volunteers can take part
- Conditions the study is for
- Healthy
- What is being tested?
- MK-7602 and Efavirenz
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 34 participants
- Where
- 1 siteUnited States
- Study dates
- 10 Feb 2025to 12 Aug 2025
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 60 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- The key inclusion criteria include but are not limited to the following:
- Has a body-mass index (BMI) of 18 to 32 kg/m^2.
Who cannot join
- The key exclusion criteria include but are not limited to the following:
- Has a history of clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and seizures) abnormalities or diseases.
- Has a history of cancer (malignancy)
- Has positive test(s) for hepatitis B surface antigen, hepatitis C antibodies, or human immunodeficiency virus (HIV)
Trial locations and contacts
1 site in 1 country.
United States1 site
Fortrea Clinical Research Unit Inc ( Site 0001)
Daytona Beach, Florida, 32117
About this study
Official title: A Clinical Study to Evaluate the Effect of Multiple Doses of Efavirenz on Single-Dose Pharmacokinetics of MK-7602 in Healthy Participants
The goal of the study is to learn what happens to levels of MK-7602 in a healthy person's body over time. Researchers will compare what happens to MK-7602 in the body when it is given with or without another medicine called efavirenz, and when it is given with or without a meal.
- Conditions
- Healthy
- Being tested
- MK-7602, Efavirenz
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
MK-7602Drug
Capsule
EfavirenzDrug
Also called MK-0831
Tablet
| Study group | Role | What they receive |
|---|---|---|
| Part 1: MK-7602 + Efavirenz | Experimental | Participants will be administered MK-7602 and efavirenz. Receives: Drug: MK-7602; Drug: Efavirenz |
| Part 2, Sequence 1: Fasted→Moderate-Fat Meal→Low-Fat Meal | Experimental | Participants will be administered MK-7602 in the fasted state, then with a moderate-fat meal, then with a low-fat meal. Receives: Drug: MK-7602 |
| Part 2, Sequence 2: Fasted→Low-Fat Meal→Moderate-Fat Meal | Experimental | Participants will be administered MK-7602 in the fasted state, then with a low-fat meal, then with a moderate-fat meal. Receives: Drug: MK-7602 |
| Part 2, Sequence 3: Moderate-Fat Meal→Low-Fat Meal→Fasted | Experimental | Participants will be administered MK-7602 with a moderate-fat meal, then with a low-fat meal, then in the fasted state. Receives: Drug: MK-7602 |
| Part 2, Sequence 4: Moderate-Fat Meal→Fasted→Low-Fat Meal | Experimental | Participants will be administered MK-7602 with a moderate-fat meal, then in the fasted state, then with a low-fat meal. Receives: Drug: MK-7602 |
| Part 2, Sequence 5: Low-Fat Meal→Fasted→Moderate-Fat Meal | Experimental | Participants will be administered MK-7602 with a low-fat meal, then in the fasted state, then with a moderate-fat meal. Receives: Drug: MK-7602 |
| Part 2, Sequence 6: Low-Fat Meal→Moderate-Fat Meal→Fasted | Experimental | Participants will be administered MK-7602 with a low-fat meal, then with a moderate-fat meal, then in the fasted state. Receives: Drug: MK-7602 |
What is being measured
The primary outcome is the main question the study is designed to answer.
Area Under the Concentration-Time Curve from Time 0 to Infinity (AUC0-Inf) of MK-7602
Blood samples will be collected to determine the AUC0-inf of MK-7602.
Measured: At designated time points (up to 4 weeks)
Area Under the Concentration-Time Curve from Time 0 to 24 hours (AUC0-24hrs) of MK-7602
Blood samples will be collected to determine the AUC0-24hr of MK-7602.
Measured: At designated time points (up to 4 weeks)
Maximum Plasma Concentration (Cmax) of MK-7602
Blood samples will be collected to determine the Cmax of MK-7602.
Measured: At designated time points (up to 4 weeks)
Time to Maximum Plasma Concentration (Tmax) of MK-7602
Blood samples will be collected to determine the Tmax of MK-7602.
Measured: Predose and at designated time points (up to 4 weeks)
Plasma Concentration at 24 Hours (C24) of MK-7602
Blood samples will be collected to determine the C24 of MK-7602.
Measured: At designated time points (up to 4 weeks)
Apparent Terminal Half-life (t1/2) of MK-7602
Blood samples will be collected to determine the t1/2 of MK-7602.
Measured: At designated time points (up to 4 weeks)
Secondary outcomes (8)
Number of Participants Who Experience an Adverse Event (AE)
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience an AE will be reported.
Measured: Up to approximately 10 weeks
Number of Participants Who Discontinue Study Treatment Due to an AE
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study treatment due to an AE will be reported.
Measured: Up to approximately 10 weeks
Part 2: AUC0-Inf of MK-7602
Blood samples will be collected to determine the AUC0-inf of MK-7602.
Measured: At designated time points (up to 4 weeks)
Part 2: AUC0-24hrs of MK-7602
Blood samples will be collected to determine the AUC0-24hr of MK-7602.
Measured: At designated time points (up to 4 weeks)
Part 2: Cmax of MK-7602
Blood samples will be collected to determine the Cmax of MK-7602.
Measured: At designated time points (up to 4 weeks)
Part 2: Tmax of MK-7602
Blood samples will be collected to determine the Tmax of MK-7602.
Measured: Predose and at designated time points (up to 4 weeks)
Part 2: C24 of MK-7602
Blood samples will be collected to determine the C24 of MK-7602.
Measured: At designated time points (up to 4 weeks)
Part 2: t1/2 of MK-7602
Blood samples will be collected to determine the t1/2 of MK-7602.
Measured: At designated time points (up to 4 weeks)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Jan 2025
- Study start10 Feb 2025
- Primary completion12 Aug 2025
- Study completion12 Aug 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HealthyStudies of the same condition, open and under way.
- More trials run by Merck Sharp & Dohme LLCThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Model description
- Part 1 has a single arm. Part 2 will enroll participants in a crossover design, randomized between 6 different treatment sequences.
- Masking
- None (open label)
- Enrolment
- 34 participants (actual)
Sponsor and investigators
- Lead sponsor
- Merck Sharp & Dohme LLC
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Medical Director, Study director, Merck Sharp & Dohme LLC
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06797674
- Sponsor's protocol ID
- 7602-005
- Status last verified
- Aug 2025
- First submitted
- 21 Jan 2025
- Last updated
- 22 Aug 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Yes: https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Study at a glance
From the registry record, last updated by the sponsor on 22 Aug 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Clinical Study to Evaluate the Effect of Multiple Doses of Efavirenz on Single-Dose Pharmacokinetics of MK-7602 in Healthy Participants
- ClinicalTrials.gov ID
- NCT06797674
- Acronym / sponsor ID
- 7602-005
- Conditions
- Healthy
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 34 participants (actual)
- Lead sponsor
- Merck Sharp & Dohme LLCIndustry (pharma, biotech, devices)
- Study start
- 10 Feb 2025 (actual)
- Primary completion
- 12 Aug 2025 (actual)
- Study completion
- 12 Aug 2025 (actual)
- First posted
- 28 Jan 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of the study is to learn what happens to levels of MK-7602 in a healthy person's body over time. Researchers will compare what happens to MK-7602 in the body when it is given with or without another medicine called efavirenz, and when it is given with or without a meal.
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Number of arms
- 7
- Model description
- Part 1 has a single arm. Part 2 will enroll participants in a crossover design, randomized between 6 different treatment sequences.
| Arm | Type | Receives |
|---|---|---|
| Part 1: MK-7602 + Efavirenz | Experimental | Drug: MK-7602, Drug: EfavirenzParticipants will be administered MK-7602 and efavirenz. |
| Part 2, Sequence 1: Fasted→Moderate-Fat Meal→Low-Fat Meal | Experimental | Drug: MK-7602Participants will be administered MK-7602 in the fasted state, then with a moderate-fat meal, then with a low-fat meal. |
| Part 2, Sequence 2: Fasted→Low-Fat Meal→Moderate-Fat Meal | Experimental | Drug: MK-7602Participants will be administered MK-7602 in the fasted state, then with a low-fat meal, then with a moderate-fat meal. |
| Part 2, Sequence 3: Moderate-Fat Meal→Low-Fat Meal→Fasted | Experimental | Drug: MK-7602Participants will be administered MK-7602 with a moderate-fat meal, then with a low-fat meal, then in the fasted state. |
| Part 2, Sequence 4: Moderate-Fat Meal→Fasted→Low-Fat Meal | Experimental | Drug: MK-7602Participants will be administered MK-7602 with a moderate-fat meal, then in the fasted state, then with a low-fat meal. |
| Part 2, Sequence 5: Low-Fat Meal→Fasted→Moderate-Fat Meal | Experimental | Drug: MK-7602Participants will be administered MK-7602 with a low-fat meal, then in the fasted state, then with a moderate-fat meal. |
| Part 2, Sequence 6: Low-Fat Meal→Moderate-Fat Meal→Fasted | Experimental | Drug: MK-7602Participants will be administered MK-7602 with a low-fat meal, then with a moderate-fat meal, then in the fasted state. |
Who may qualify
- Ages
- 18 to 60 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (2 listed)
- Has a body-mass index (BMI) of 18 to 32 kg/m^2.
Key exclusion criteria (4 listed)
- Has a history of clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and seizures) abnormalities or diseases.
- Has a history of cancer (malignancy)
- Has positive test(s) for hepatitis B surface antigen, hepatitis C antibodies, or human immunodeficiency virus (HIV)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| MK-7602Capsule | Drug | Part 1: MK-7602 + Efavirenz, Part 2, Sequence 1: Fasted→Moderate-Fat Meal→Low-Fat Meal, Part 2, Sequence 2: Fasted→Low-Fat Meal→Moderate-Fat Meal, Part 2, Sequence 3: Moderate-Fat Meal→Low-Fat Meal→Fasted, Part 2, Sequence 4: Moderate-Fat Meal→Fasted→Low-Fat Meal, Part 2, Sequence 5: Low-Fat Meal→Fasted→Moderate-Fat Meal, Part 2, Sequence 6: Low-Fat Meal→Moderate-Fat Meal→Fasted |
| EfavirenzAlso: MK-0831Tablet | Drug | Part 1: MK-7602 + Efavirenz |
Primary outcome
Area Under the Concentration-Time Curve from Time 0 to Infinity (AUC0-Inf) of MK-7602
Time frame: At designated time points (up to 4 weeks)
Blood samples will be collected to determine the AUC0-inf of MK-7602.
Area Under the Concentration-Time Curve from Time 0 to 24 hours (AUC0-24hrs) of MK-7602
Time frame: At designated time points (up to 4 weeks)
Blood samples will be collected to determine the AUC0-24hr of MK-7602.
Maximum Plasma Concentration (Cmax) of MK-7602
Time frame: At designated time points (up to 4 weeks)
Blood samples will be collected to determine the Cmax of MK-7602.
Time to Maximum Plasma Concentration (Tmax) of MK-7602
Time frame: Predose and at designated time points (up to 4 weeks)
Blood samples will be collected to determine the Tmax of MK-7602.
Plasma Concentration at 24 Hours (C24) of MK-7602
Time frame: At designated time points (up to 4 weeks)
Blood samples will be collected to determine the C24 of MK-7602.
Apparent Terminal Half-life (t1/2) of MK-7602
Time frame: At designated time points (up to 4 weeks)
Blood samples will be collected to determine the t1/2 of MK-7602.
8 secondary outcomes
Number of Participants Who Experience an Adverse Event (AE)
Time frame: Up to approximately 10 weeks
Number of Participants Who Discontinue Study Treatment Due to an AE
Time frame: Up to approximately 10 weeks
Part 2: AUC0-Inf of MK-7602
Time frame: At designated time points (up to 4 weeks)
Part 2: AUC0-24hrs of MK-7602
Time frame: At designated time points (up to 4 weeks)
Part 2: Cmax of MK-7602
Time frame: At designated time points (up to 4 weeks)
Part 2: Tmax of MK-7602
Time frame: Predose and at designated time points (up to 4 weeks)
Part 2: C24 of MK-7602
Time frame: At designated time points (up to 4 weeks)
Part 2: t1/2 of MK-7602
Time frame: At designated time points (up to 4 weeks)
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Aug 2025.
- Merck Clinical Trials InformationLink provided by the sponsor.
- Individual participant dataSharing planned: Yes. https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Related trials for Healthy
Recruiting
THE EFFECTS OF GAME-BASED EXERCISE PROGRAMS
Physical Activity, Body Image
Not yet recruitingPhase 1
A Phase I Study of GLR2053 Tablets in Chinese Healthy Adult Participants
Atopic Dermatitis
Recruiting
Colon-delivered Riboflavin and Gut Microbiota Composition
Microbiome Dysbiosis, Gut Health
Not yet recruiting
Neuroergonomic Analysis of a Brain-Computer Interface Device (BCI)
Healthy Volunteers - Male and Female
RecruitingPhase 1
First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
Healthy Volunteer, Atopic Dermatitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Medical Director study director
Merck Sharp & Dohme LLC
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing MK-7602 and Efavirenz in people with Healthy, run by Merck Sharp & Dohme LLC at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 22 Aug 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Area Under the Concentration-Time Curve from Time 0 to Infinity (AUC0-Inf) of MK-7602 (time frame: At designated time points (up to 4 weeks)). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Aug 2025.